Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 6, 2007 Brian Lawler	Celgene Mints the Green Stuff Biotech firm Celgene reports its 2006 financial results and provides an update for its 2007 guidance. Biopharma investors know it's not the past that matters the most in this sector; it's the outlook.
The Motley Fool January 13, 2009 Brian Orelli	Celgene's Still Surging With returns over the last five years that just about any investor would love to have, it might be fair to wonder whether Celgene can keep it up. It seems it can.
The Motley Fool January 11, 2010 Brian Orelli	Celgene Revs Up for a New Year Preliminary 2009 sales released at the J.P. Morgan Health Care Conference have sales up about 20% year over year and Celgene is guiding for 20% revenue growth next year as well.
The Motley Fool May 8, 2007 Brian Lawler	Unstoppable Celgene The biotech powerhouse continues its strong financial results as Revlimid sales grow.
The Motley Fool April 28, 2011 Brian Orelli	Celgene Gets No Love The market shrugs off a solid quarter.
The Motley Fool October 30, 2006 Brian Lawler	Millennium Is So Last Century The drug company released its third-quarter results last week, and there is not much particularly exciting therein. None of its drug candidates is in late-stage testing and all are years away from approval, except for follow-on indications for Velcade. Investors, take note.
The Motley Fool January 28, 2011 Brian Orelli	Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase.
The Motley Fool October 23, 2009 Brian Orelli	Not 50% Growth, but We'll Take It Double-digit growth is still pretty good for Celgene.
The Motley Fool October 27, 2006	A Healthy Celgene: Fool by Numbers The biotech released third-quarter earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool April 30, 2010 Brian Orelli	New CEO, Same Old Double-Digit Increases Another strong quarter from Celgene.
The Motley Fool November 20, 2007 Brian Orelli	Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future.
The Motley Fool January 8, 2007 Brian Lawler	Millennium Looks Ahead Shares of the biopharmaceutical company ended the year more than 10% higher, despite the presence of increased competition for its cancer treatment Velcade and all sorts of attempted merger and acquisition activity within the company. The pharmaceutical foresees a mixed 2007.
The Motley Fool July 29, 2010 Brian Orelli	This Best Biotech Is Cheaper Than You Think The cancer-drug specialist justifies its valuation quite effectively with a stellar second-quarter performance.
The Motley Fool January 29, 2010 Brian Orelli	Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead.
The Motley Fool July 24, 2009 Brian Orelli	Juicing Up the Earnings Report How did Celgene turn an earnings release that met analysts' expectations while lowering revenue guidance on one of its drugs into an 18.6% increase in share price yesterday?
The Motley Fool October 6, 2010 Brian Orelli	Celgene Is All Grown Up An acquirer is on the prowl.
The Motley Fool June 30, 2010 Brian Orelli	Celgene Jumps on a Platform Investors don't seem too enamored with Celgene's announcement that it's purchasing fellow cancer drugmaker Abraxis Bioscience although it looks like a good move in the long term.
The Motley Fool February 2, 2007	Celgene Looks Stellar: Fool by Numbers The biopharmaceutical released fourth-quarter 2006 earnings. Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool December 8, 2009 Brian Orelli	Early and Often: A Drug Investor's Dream Celgene has two goals for its multiple myeloma drug, Revlimid: to have patients begin taking it earlier in the progression of their disease, and to have them stay on the drug longer.
The Motley Fool January 30, 2009 Brian Orelli	Celgene's Double Take Still Looks Good No one is going to stop using Celgene's cancer-fighting products just because the economy is in the tank, so the company should have no problem hitting or even exceeding its growth estimates the way it has before.
The Motley Fool March 31, 2009 Brian Orelli	A Good Start for a Potential Blockbuster Novartis' FDA approval for Afinitor is nice, but it needs another indication to be a blockbuster.
The Motley Fool January 31, 2008 Brian Lawler	Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug.
The Motley Fool September 24, 2007 Brian Lawler	An Array of Good News Small pharmaceutical firm Array BioPharma signs a big partnership deal with Celgene. Investors, take note.
The Motley Fool June 8, 2010 Rich Smith	This Just In: Upgrades and Downgrades Is Celgene the new Genentech? Maybe not -- but it's cheap.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
The Motley Fool December 8, 2010 Brian Orelli	Winners and Losers at the Hematology Society Meeting The American Society of Hematology annual meeting wrapped up yesterday, and as with pretty much every medical meeting, we've got some winning and losing blood-cancer drugs.
The Motley Fool June 9, 2010 Brian Orelli	ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology.
The Motley Fool November 4, 2011 Luke Timmerman	Celgene to Pump $45M Into Quanticel to Discover Cancer Drugs Celgene strikes an unusual agreement.
The Motley Fool December 9, 2009 Brian Orelli	Rising From the ASHes At the Super Bowl of blood cancer, the American Society of Hematology's annual conference, the presentations by drug companies made a few stocks catch on fire, while a couple burned up a little.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool June 14, 2007 Tim Beyers	Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? Celgene... Chesapeake Energy... Einstein Noah Restaurant Group... Kinder Morgan Management... Osiris Therapeutics... etc.
The Motley Fool December 14, 2006 Brian Lawler	Celgene Faces a Generic Challenge An abbreviated application is only an opening salvo in Barr's challenge to Celgene's Thalomid patents. Investors, take note.
Chemistry World July 29, 2015 Phillip Broadwith	Celgene to buy immune-inflammatory specialist Receptos The deal gives Celgene access to Receptos's pipeline of inflammation and immunology treatments.
The Motley Fool May 24, 2010 Brian Orelli	ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse.
The Motley Fool December 29, 2005 Brian Gorman	PBMs at a Crossroads One prediction that's sure to come true next year -- drug prices will rise. Pharmacy benefit management (PBM) companies will respond. But the year ahead promises to be trickier for investors seeking to profit from PBMs.
The Motley Fool March 26, 2008 Brian Lawler	Celgene Brings in an Orphan The Food and Drug Administration grants a Celgene drug orphan designation. Amrubicin may have an easier time in development for use in a limited patient population.
The Motley Fool April 1, 2009 Brian Orelli	Conservative Celgene's Conundrum The drugmaker said it expected to make the low end of its previous guidance ranges for non-GAAP revenue and earnings per share for the year. It's not bad news, but it hurt the company nonetheless.
The Motley Fool March 23, 2005 John Reeves	Stock Madness 2005: Lloyds TSB vs. Celgene Backgrounds on two stocks you might want to consider: Lloyds and Celgene.
The Motley Fool July 26, 2010 Brian Orelli	Up 20%! Guess That Hedge Wasn't Needed Onyx reports positive data for its recently acquired multiple myeloma drug.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
Chemistry World July 8, 2015 Phillip Broadwith	Celgene backs immunotherapy with Juno collaboration US biopharmaceutical firm Celgene is to bolster its position in the emerging field of cell therapy through a collaboration with biotech Juno Therapeutics.
The Motley Fool January 11, 2011 Brian Orelli	An Undeserved Kick in the Pants Celgene gets knocked around.
The Motley Fool July 3, 2008 Brian Lawler	Celgene Savors the Schadenfreude Bad news for a rival is a bonanza for drugmaker Celgene.
The Motley Fool March 21, 2005 Alyce Lomax	Stock Madness 2005: Dell vs. Celgene The computer maker and the biotech company vie for a berth in the next round of "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool October 12, 2009 Brian Orelli	Onyx Strikes Gold A nice pipeline pickup for this pharmaceutical company.
Pharmaceutical Executive September 1, 2011	Pharm Exec's 10th Annual Industry Audit A survey of the landscape of pharma financials over the past year, and a look at which companies rode the wave to the top of the industry in delivering value to shareholders.
The Motley Fool December 29, 2011 Brian Orelli	What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key.
The Motley Fool October 11, 2011 Arlene Weintraub	Agios and Celgene: Anatomy of an Ultra-Valuable Biotech Marriage An unprecedented cancer drug development deal.
The Motley Fool November 12, 2009 Brian Orelli	The Life-and-Death Situation That Isn't Branded-drug makers aren't playing fair because they refuse to sell samples to generic drug makers.
Chemistry World December 4, 2013 Phillip Broadwith	Celgene buys into anticancer antibodies US firms Celgene and OncoMed have tied up a deal to develop and commercialize biological therapies for cancer.